Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.37 USD
Change Today -0.32 / -0.95%
Volume 22.6M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

235 East 42nd Street

New York, NY 10017

United States

Phone: 212-733-2323

Fax:

Pfizer Inc. operates as a research-based, biopharmaceutical company worldwide. The company’s global portfolio includes medicines and vaccines, as well as various consumer healthcare products. The company collaborates with healthcare providers, governments, and local communities to support and expand access to healthcare worldwide. Commercial Operations In 2014, the company began managing its commercial operations through a new global commercial structure consisting of two businesses, such as an Innovative Products business and an Established Products business. The Innovative Products business includes two operating segments, such as the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Innovative Products Business GIP: This segment is focused on developing, registering, and commercializing novel, value-creating medicines that improve patients’ lives. These therapeutic areas include inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health; and include major brands, such as Xeljanz, Eliquis, and Lyrica (the United States (U.S.) and Japan). GIP has a pipeline of medicines in inflammation, cardiovascular/metabolic disease, neuroscience and pain, and rare diseases. VOC: This segment focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets various over-the-counter (OTC) products. Established Products Business GEP: This segment includes the brands that have lost market exclusivity, and generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in various major markets, and to a much smaller extent, generic pharmaceuticals. Additionally, this segment includes the company’s sterile injectable products and biosimilar development portfolio. Biopharmaceutical Products In 2014, the company’s biopharmaceutical business was managed through GIP, GEP, and the vaccines and oncology businesses of VOC. The company’s major biopharmaceutical products, including Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, Norvasc, the Premarin family of products, Eliquis, and Xeljanz. The company has collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including Aricept, Enbrel (in the U.S. and Canada), Spiriva, and Rebif, each of which has expired or would expire in various markets. In addition, Eliquis is developed and is being commercialized in collaboration with Bristol-Myers Squibb Company. Consumer Healthcare The Consumer Healthcare business holds positions in various geographic markets, including the U.S., China, Canada, Germany, Italy, and Brazil. Major categories and product lines in the company’s Consumer Healthcare business comprise: Dietary Supplements: Centrum brands (including Centrum, Centrum Silver, Centrum Men’s and Women’s, Centrum Specialist, Centrum Flavor Burst, and Centrum Kids), Caltrate, and Emergen-C. Pain Management: Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children’s Advil, Infants’ Advil, and Advil Migraine), and ThermaCare. Gastrointestinal: Nexium 24HR/Nexium Control. Respiratory: Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp. Personal Care: ChapStick and Preparation H. The company has an agreement with AstraZeneca PLC for the global OTC rights for Nexium, a major prescription drug approved to treat the symptoms of gastroesophageal reflux disease. The company owns the consumer healthcare business of Ferrosan, a Danish company that sells science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. International Operations The company has operations outside the U.S. In 2014, for developed and emerging markets, these operations were managed thr

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $33.37 USD -0.32

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $115.04 USD -0.97
Merck & Co Inc $57.67 USD +0.07
Nestle SA SFr.68.60 CHF -0.40
Roche Holding AG SFr.265.10 CHF -1.30
Procter & Gamble Co/The $79.93 USD +0.21
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 23.1x
Price/Sales 4.2x
Price/Book 3.1x
Price/Cash Flow 15.8x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.